2024
Targeting Pseudomonas aeruginosa biofilm with an evolutionary trained bacteriophage cocktail exploiting phage resistance trade-offs
Kunisch F, Campobasso C, Wagemans J, Yildirim S, Chan B, Schaudinn C, Lavigne R, Turner P, Raschke M, Trampuz A, Gonzalez Moreno M. Targeting Pseudomonas aeruginosa biofilm with an evolutionary trained bacteriophage cocktail exploiting phage resistance trade-offs. Nature Communications 2024, 15: 8572. PMID: 39362854, PMCID: PMC11450229, DOI: 10.1038/s41467-024-52595-w.Peer-Reviewed Original ResearchConceptsResistance trade-offBacteriophage host rangeViruses of bacteriaHuman microbial infectionsMultidrug-resistant bacterial infectionsTwo-phage cocktailMultidrug-resistant Pseudomonas aeruginosa strainsLytic bacteriophagesBiofilm-associatedEvolution assaysPlanktonic culturesBacteriophage cocktailHost rangeBacteriophageHost spectrumBacteriophage therapyCocktail designCombat biofilmsTreated bacteriaMicrobial infectionsAntimicrobial efficacyBacterial suppressionPolymerase chain reactionBacterial infectionsClinical outcomesLytic bacteriophages induce the secretion of antiviral and proinflammatory cytokines from human respiratory epithelial cells
Zamora P, Reidy T, Armbruster C, Sun M, Van Tyne D, Turner P, Koff J, Bomberger J. Lytic bacteriophages induce the secretion of antiviral and proinflammatory cytokines from human respiratory epithelial cells. PLOS Biology 2024, 22: e3002566. PMID: 38652717, PMCID: PMC11037538, DOI: 10.1371/journal.pbio.3002566.Peer-Reviewed Original ResearchConceptsLytic phagesLytic bacteriophagesPhage therapyAirway epithelial cellsPseudomonas aeruginosa phagesEpithelial cellsMultidrug resistanceAirway epitheliumCystic fibrosisProinflammatory cytokinesHuman respiratory epithelial cellsPhage exposurePhage familiesMammalian cell responsesHuman airway epithelial cellsInternalized phageTreat multidrug-resistantPhageBacterial isolatesTranscriptional profilesRespiratory epithelial cellsHuman hostChronic respiratory disordersBacterial biofilmsBacteriophageOptimized preparation pipeline for emergency phage therapy against Pseudomonas aeruginosa at Yale University
Würstle S, Lee A, Kortright K, Winzig F, An W, Stanley G, Rajagopalan G, Harris Z, Sun Y, Hu B, Blazanin M, Hajfathalian M, Bollyky P, Turner P, Koff J, Chan B. Optimized preparation pipeline for emergency phage therapy against Pseudomonas aeruginosa at Yale University. Scientific Reports 2024, 14: 2657. PMID: 38302552, PMCID: PMC10834462, DOI: 10.1038/s41598-024-52192-3.Peer-Reviewed Original ResearchMeSH KeywordsBacteriophagesHumansPhage TherapyPseudomonas aeruginosaPseudomonas InfectionsPseudomonas PhagesUniversitiesConceptsEvolutionary selection pressurePhage characterizationPhage therapyPersistent bacterial infectionsBacteriophage therapyPhageSelection pressurePseudomonas aeruginosaInvestigational new drug applicationBacterial infectionsNew Drug ApplicationTherapyDrug applicationClinical applicationAutographiviridaeBacteriaPotential strategy
2023
Developing Phage Therapy That Overcomes the Evolution of Bacterial Resistance
Oromí-Bosch A, Antani J, Turner P. Developing Phage Therapy That Overcomes the Evolution of Bacterial Resistance. Annual Review Of Virology 2023, 10: 503-524. PMID: 37268007, DOI: 10.1146/annurev-virology-012423-110530.Peer-Reviewed Original ResearchConceptsPhage therapyPhage resistanceBacterial resistanceEvolution of phage resistancePhage-resistant bacteriaEvolution of bacterial resistanceBacteria-specific virusesTreatment of intractable infectionsAlternative antimicrobial strategiesPersonalized medicine treatmentsPhage strategyClinically favorable outcomesBacterial pathogensBacterial populationsPhageTarget bacteriaAntibiotic resistanceAntimicrobial strategiesIntractable infectionsWaning efficacyFavorable outcomeBacterial infectionsBacteriaTherapyPatient treatment
2022
Inhaled Bacteriophage Therapy for Multi-Drug Resistant Achromobacter.
Winzig F, Gandhi S, Lee A, Würstle S, Stanley G, Capuano I, Neuringer I, Koff J, Turner P, Chan B. Inhaled Bacteriophage Therapy for Multi-Drug Resistant Achromobacter. The Yale Journal Of Biology And Medicine 2022, 95: 413-427. PMID: 36568830, PMCID: PMC9765334.Peer-Reviewed Original ResearchConceptsCF patientsCystic fibrosisChronic pulmonary infectionGlobal public health threatBacterial lung infectionsChallenging clinical problemPublic health threatChronic bacterial lung infectionsPulmonary infectionRespiratory statusLung infectionClinical problemBacteriophage therapyInfectionAntimicrobial-resistant bacteriaTherapyHealth threatPhage therapyPatientsAMR infectionsResistant bacteriaLytic bacteriophagesPossible benefitsChemical antibioticsCurrent study
2019
Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria
Kortright KE, Chan BK, Koff JL, Turner PE. Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria. Cell Host & Microbe 2019, 25: 219-232. PMID: 30763536, DOI: 10.1016/j.chom.2019.01.014.Peer-Reviewed Original ResearchConceptsPhage therapyRecent case reportsAntibiotic-resistant bacteriaResistant bacterial infectionsCase reportChemical antibioticsClinical trialsClinical utilityIntractable infectionsAnimal modelsTherapyBacterial infectionsWestern medicineCombat Antibiotic-Resistant BacteriaPhage therapy researchInfectionAntibioticsTherapy researchPhage resistanceClinicTrials